Predictors of Antiviral Therapy in a Post-Transfusion Cohort of Hepatitis C Patients

Maciej Witkos; Qi-Long Yi; Jenny Heathcote; Moira K Kapral; Murray D Krahn

doi:10.1155/2006/638272

Canadian Journal of Gastroenterology (Jan 2006)

Predictors of Antiviral Therapy in a Post-Transfusion Cohort of Hepatitis C Patients

Maciej Witkos,
Qi-Long Yi,
Jenny Heathcote,
Moira K Kapral,
Murray D Krahn

Affiliations

Maciej Witkos: Department of Health Policy, Management and Evaluation, University of Toronto, Toronto General Hospital, Canada
Qi-Long Yi: Department of Public Health Sciences, Ontario Cancer Institute, Princess Margaret Hospital, Canada
Jenny Heathcote: Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada
Moira K Kapral: Department of Health Policy, Management and Evaluation, University of Toronto, Toronto General Hospital, Canada
Murray D Krahn: Department of Health Policy, Management and Evaluation, University of Toronto, Toronto General Hospital, Canada

DOI: https://doi.org/10.1155/2006/638272
Journal volume & issue: Vol. 20, no. 2
pp. 107 – 111

Abstract

Read online

INTRODUCTION: In the past, antiviral therapy has been given to 15% to 30% of patients infected with hepatitis C virus (HCV). The efficacy of therapy has recently improved with the addition of ribavirin and pegylated interferon. The aim of the present study was to identify the clinical, socioeconomic and health-system predictors of antiviral treatment for HCV.

Published in Canadian Journal of Gastroenterology

ISSN: 0835-7900 (Print); 1916-7237 (Online)
Publisher: Hindawi Limited
Country of publisher: United Kingdom
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Diseases of the digestive system. Gastroenterology
Website: https://onlinelibrary.wiley.com/journal/1720

About the journal